سعر تافانيك 500مجم/100مل وريدي 2024

Levofloxacin 500 mg/100 ml (5 mg/ml) solution for intravenous infusion (fluoroquinolone antibacterial), 1 vial.

• Adults: acute pyelonephritis and complicated urinary tract infections, chronic bacterial prostatitis, inhalation anthrax (post-exposure prophylaxis and curative treatment); and, only when other commonly recommended antibacterials are considered inappropriate, community-acquired pneumonia and complicated skin and soft tissue infections.Population: AdultsHealth Products Regulatory Authority (HPRA), Ireland

• Common: insomnia, headache, dizziness, diarrhoea, vomiting, nausea, increased hepatic enzymes; infusion-site reaction/phlebitis with the IV form.International label, same product · Health Products Regulatory Authority (HPRA), Ireland

• Hypersensitivity to levofloxacin, other quinolones or excipients; epilepsy; history of tendon disorders related to fluoroquinolones; children or growing adolescents; pregnancy; breastfeeding.International label, same product · Health Products Regulatory Authority (HPRA), Ireland

• Tendinitis and tendon rupture (especially Achilles) can occur within 48 hours of starting and up to months after stopping; risk higher in older patients, renal impairment, organ transplant and with corticosteroids.International label, same product · Health Products Regulatory Authority (HPRA), Ireland
• Use with caution in patients with risk factors for QT prolongation (congenital long QT, QT-prolonging drugs, uncorrected electrolyte imbalance, cardiac disease).International label, same product · Health Products Regulatory Authority (HPRA), Ireland
• Fluoroquinolones increase the risk of aortic aneurysm and dissection and of heart valve regurgitation; use only after careful benefit-risk assessment in patients with these conditions or risk factors.International label, same product · Health Products Regulatory Authority (HPRA), Ireland

• Vitamin K antagonists (e.g. warfarin)Increased PT/INR and/or bleeding, which may be severe; monitor coagulation tests.Health Products Regulatory Authority (HPRA), Ireland
• Drugs prolonging the QT interval (class IA/III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics)Use with caution because of additive QT prolongation risk.Health Products Regulatory Authority (HPRA), Ireland
• Theophylline, NSAIDs and other drugs lowering the seizure thresholdPronounced lowering of the cerebral seizure threshold may occur.Health Products Regulatory Authority (HPRA), Ireland

• Limited human data; because of possible quinolone damage to weight-bearing cartilage of the growing organism, levofloxacin must not be used in pregnant women.International label, same product · Health Products Regulatory Authority (HPRA), Ireland
• Contraindicated in breastfeeding women; human milk excretion data are insufficient but other fluoroquinolones are excreted in milk.International label, same product · Health Products Regulatory Authority (HPRA), Ireland

• Levofloxacin: Levofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes needed for bacterial DNA replication (WHO ATC fluoroquinolone; US label section 12.1).